The treatment of Tourette's syndrome: Multimodal, developmental intervention

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 1, 1998, Pages 62-74

  Peterson, Bradley S ^a   Cohen, Donald J ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; AMFEBUTAMONE; ANXIOLYTIC AGENT; BUSPIRONE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CLONAZEPAM; CLONIDINE; CLOZAPINE; DESIPRAMINE; DOPAMINE RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; FLUVOXAMINE MALEATE; GUANFACINE; HALOPERIDOL; METHYLPHENIDATE; NEUROLEPTIC AGENT; NICOTINE; NORTRIPTYLINE; PIMOZIDE; RISPERIDONE; SELEGILINE; SEROTONIN 2 ANTAGONIST; TRICYCLIC ANTIDEPRESSANT AGENT;

AFFECTIVE NEUROSIS; ATTENTION DEFICIT DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COMORBIDITY; GILLES DE LA TOURETTE SYNDROME; HUMAN; IMAGERY; OBSESSION; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SIDE EFFECT; TIC; TRANSDERMAL DRUG ADMINISTRATION;

ADAPTATION, PSYCHOLOGICAL; ADOLESCENT; ADRENERGIC AGONISTS; ADULT; AGE FACTORS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLONIDINE; COMBINED MODALITY THERAPY; COMORBIDITY; DOPAMINE AGONISTS; FLUOXETINE; HUMANS; OBSESSIVE-COMPULSIVE DISORDER; PSYCHOTHERAPY; SOCIAL SUPPORT; TOURETTE SYNDROME;

EID: 0031908880     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (73)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, DC: American Psychiatric Association; 1994
2. Achenbach TM, Edelbrock CS. The classification of child psychopathology: a review and analysis of empirical efforts. Psychol Bull 1978;85: 1275-1301
3. Nomoto F, Machiyama Y. An epidemiological study of tics. Jpn J Psychiatry Neurol 1990;44:649-655
4. Peterson BS, Leckman JF, Cohen DJ. Tourette's syndrome: a genetically predisposed and an environmentally specified developmental psychopathology. In: Cicchetti D, Cohen DJ, eds. Developmental Psychopathology, vol. 2: Risk, Disorder, and Adaptation. New York, NY: John Wiley & Sons: 1995:213-242
5. Pauls DL, Towbin KE, Leckman JF, et al. Gilles de la Tourette's syndrome and obsessive-compulsive disorder: evidence supporting a genetic relationship. Arch Gen Psychiatry 1986;43:1180-1182
6. Pauls DL, Leckman JF, Cohen DJ. Familial relationship between Gilles de la Tourette's syndrome, attention deficit disorder, learning disabilities, speech disorders, and stuttering. J Amer Acad Child Adolesc Psychiatry 1993;32:1044-1050
7. Apter A, Pauls DL, Bleich A, et al. An epidemiologic study of Gilles de la Tourette's syndrome in Israel. Arch Gen Psychiatry 1993;50:734-738
8. Pauls DL, Leckman JF, Cohen DJ. Evidence against a genetic relationship between Tourette's syndrome and anxiety, depression, panic and phobic disorders. Br J Psychiatry 1994;164:215-221
9. Berkson JB. Limitations of the application of fourfold table analysis to hospital data. Biometrics 1946;2:47-51
10. Masten AS, Coatsworth JD. Competence, resilience, and psychopathology. In: Cicchetti D, Cohen DJ, eds. Developmental Psychopathology, vol. 2: Risk, Disorder, and Adaptation. New York. NY: John Wiley & Sons; 1995:715-752
11. Harrington R, Fudge H, Rutter M, et al. Adult outcomes of childhood and adolescent depression, I: psychiatric status. Arch Gen Psychiatry 1990;47: 465-473
12. Leonard HL, Lenane MC, Swedo SE, et al. Tics and Tourette's disorder: a 2- to 7-year follow-up of 54 obsessive-compulsive children. Am J Psychiatry 1992;149:1244-1251
13. Mannuzza S, Klein RG, Bessler A, et al. Adult outcome of hyperactive boys. Arch Gen Psychiatry 1993;50:565-576
14. Leckman JF, Walker DE, Cohen DJ. Premonitory urges in Tourette's syndrome. Am J Psychiatry 1993;150:98-102
15. Bruun RD. The natural history of Tourette's syndrome. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders: Clinical Understanding and Treatment. New York, NY: John Wiley & Sons; 1988:21-39
16. Swedo SE, Rapoport JL, Leonard H, et al. Obsessive-compulsive disorder in children and adolescents: clinical phenomenology of 70 consecutive cases. Arch Gen Psychiatry 1989;46:335-341
17. Leonard HL, Goldberger EL, Rapoport JL, et al. Childhood rituals: normal development or obsessive-compulsive symptoms? J Am Acad Child Adolese Psychiatry 1990;29:17-23
18. Kohen DP, Botts P. Relaxation-imagery (self-hypnosis) in Tourette syndrome: experience with four children. J Clin Hypnosis 1987;29:227-237
19. Azrin NH, Peterson AL. Treatment of Tourette syndrome by habit reversal: a waiting-list control group comparison. Behav Ther 1990;21:305-318
20. Mahler SM, Luke JA, Daltroff W. Clinical and follow-up study of the tic syndrome in children. Am J Orthopsychiatry 1945;15:631-647
21. Clark L. SOS! Help for Parents. Bowling Green, Ky: Parents Press; 1993
22. Chappell P, Riddle M, Anderson G, et al. Enhanced stress responsivity of Tourette syndrome patients undergoing lumbar puncture. Biol Psychiatry 1994;36:35-43
23. Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette's syndrome. Lancet 1979;2:551-553
24. Cohen DJ, Detlor J, Young JG, et al. Clonidine ameliorates Gilles de la Tourette syndrome. Arch Gen Psychiatry 1980;37:1350-1357
25. 2-noradrenergic mechanisms to prefrontal cortical cognitive function. Arch Gen Psychiatry 1996;53:448-455
26. Leckman JF, Hardin MT, Riddle MA, et al. Clonidine treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1991;48:324-328
27. Singer HS, Brown J, Quaskey S, et al. The treatment of attention-deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo-controlled study with clonidine and desipramine. Pediatrics 1995;95:74-81
28. Seignot MJN. Un cas de maladie des tics de Gilles de la Tourette gueri par le R-1625. Ann Med Psychol 1961;119:578-579
29. Shapiro AK, Shapiro E. Treatment of tic disorders with haloperidol. In: Cohen DJ, Bruun RD, Leckman JF, eds. Tourette's Syndrome and Tic Disorders. New York, NY: John Wiley & Sons; 1988:268-280
30. Cohen DJ, Riddle MA, Leckman JF. Pharmacotherapy of Tourette's syndrome and associated disorders. In: Shaffer D, ed. The Psychiatric Clinics of North America: Pediatric Psychopharmacology, vol. 15. Philadelphia, Pa: Saunders; 1992:109-129
31. Ross MS, Moldofsky H. A comparison of pimozide and haloperidol in the treatment of Gilles de la Tourette's syndrome. Am J Psychiatry 1978;135: 585-587
32. Shapiro AK, Shapiro E, Eisenkraft GJ. Treatment of Gilles de la Tourette Syndrome with pimozide. Am J Psychiatry 1983;140:1183-1186
33. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989;46:722-730
34. Lombroso PJ, Scahill L, King RA, et al. Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. J Am Acad Child Adolesc Psychiatry 1995;34:1147-1152
35. van der Linden C, Briggeman R, van Woerkom TCAM. Serotonin-dopamine antagonist and Gilles de la Tourette's syndrome: an open pilot dose-titration study with risperidone. Mov Disord 1994;9:687-688
36. Parent A. Serotonergic innervation of the basal ganglia. J Comp Neurol 1990;299:1-16
37. Peterson B, Riddle MA, Cohen DJ, et al. Reduced basal ganglia volumes in Tourette's syndrome using three-dimensional reconstruction techniques from magnetic resonance images. Neurology 1993;43:941-949
38. Singer HS, Reiss AL, Brown JE, et al. Volumetric MRI changes in basal ganglia of children with Tourette's syndrome. Neurology 1993;43:950-956
39. Braun AR, Stoetter B, Randolph C, et al. The functional neuroanatomy of Tourette's syndrome: an FDG-PET study, I: regional changes in cerebral glucose metabolism differentiating patients and controls. Neuropsychopharmacology 1993;9:277-291
40. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136: 317-320
41. Gonce C, Barbeau A. Seven cases of Gilles de la Tourette's syndrome: partial relief with clonazepam: a pilot study. Can J Neurol Sci 1977;4:279-283
42. Steingard RJ, Goldberg M, Lee D, et al. Adjunctive clonazepam treatment of tic symptoms in children with comorbid tic disorders and ADHD. J Am Acad Child Adolesc Psychiatry 1994;33:394-399
43. Sanberg PR, McConville BJ, Fogelson HM, et al. Nicotine potentiates the effects of haloperidol in animals and in patients with Tourette syndrome. Biomed Pharmacother 1989;43:19-23
44. Dursun SM, Reveley MA, Bird R, et al. Longlasting improvement of Tourette's syndrome with transdermal nicotine [letter]. Lancet 1994;344: 1577
45. Silver AA, Shytle RD, Philipp MK, et al. Case study: long-term potentiation of neuroleptics with transdermal nicotine in Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1996;35:1631-1636
46. Casas M, Alvarez E, Duro P, et al. Antiandrogenic treatment of obsessive-compulsive neurosis. Acta Psychiatr Scand 1986;73:221-222
47. Swedo SE, Rapoport JL. Neurochemical and neuroendocrine considerations of obsessive-compulsive disorders in childhood. In: Deutsch S, ed. Application of Basic Neuroscience to Child Psychiatry. New York, NY: Plenum; 1990:275-284
48. Sandyk R. Clomiphene citrate in Tourette's syndrome. Int J Neurosci 1988; 43:103-106
49. Peterson BS, Leckman JF, Scahill L, et al. Steroid hormones and Tourette's syndrome: early experience with antiandrogen therapy. J Clin Psychopharmacol 1994;14:131-135
50. Peterson BS, Leckman JF, Scahill L, et al. Steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome. Psychoneuroendocrinology 1992;17:553-563
51. Biederman J, Newcorn J, Sprich S. Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991;148:564-577
52. Lipkin PH, Goldstein JJ, Adesman AR. Tics and dyskinesias associated with stimulant treatment in attention-deficit hyperactivity disorder. Arch Pediatr Adolesc Med 1994;148:859-861
53. Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 1985;35:1346-1348
54. Golden GS. Gilles de la Tourette's syndrome following methylphenidate administration. Devel Med Child Neurol 1974;16:76-78
55. Gadow KD, Sverd J, Sprafkin J, et al. Efficacy of methylphenidate for attention-deficit hyperactivity disorder in children with tic disorder. Arch Gen Psychiatry 1995;52:444-455
56. Crum RM, Anthony, JC. Cocaine use and other suspected risk factors for obsessive-compulsive disorder: a prospective study with data from the Epidemiologic Catchment Area surveys. Drug Alcohol Depend 1993;31: 281-295
57. Biederman J, Baldessarini R, Wright V, et al. A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder, I: efficacy. J Am Acad Child Adolesc Psychiatry 1989;28:777-784
58. Donnelly M, Zametkin AJ, Rapoport JL, et al. Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels, and clinical response. Clin Pharmacol Ther 1986;39:72-81
59. Garfinkel BD, Wender PH, Sloman L, et al. Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Adolesc Psychiatry 1983;22:343-348
60. Spencer T, Biederman J, Kerman K, et al. Desipramine treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993;32: 354-60
61. Riddle MA, Hardin MT, Cho SC, et al. Desipramine treatment of boys with attention-deficit hyperactivity disorder and tics: preliminary clinical experience. J Am Acad Child Adoles Psychiatry 1988;27:811-814
62. Abramowicz M. Sudden death in children with a tricyclic antidepressant. Med Lett Drugs Ther 1990;32:53
63. Biederman J, Thisted RA, Greenhill LL, et al. Estimation of the association between desipramine and the risk for sudden death in 5- to 14-year-old children. J Clin Psychiatry 1995;56:87-93
64. Riddle MA, Geller B, Ryan N. Another sudden death in a child treated with desipramine. J Am Acad Child Adolesc Psychiatry 1993;32:792-797
65. Spencer T, Biederman J, Wilens T, et al. Nortriptyline treatment of children with attention-deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:205-210
66. Hunt RD, Minderaa RB, Cohen DJ. Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial. J Am Acad Child Adolesc Psychiatry 1985;24: 617-629
67. Hunt RD, Arnsk AFT, Asbell MD. An open trial of guanfacine in the treatment of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 1995;34:50-54
68. Chappell PB, Riddle MA, Scahill L, et al. Guanfacine treatment of comorbid attention deficit hyperactivity disorder and Tourette's syndrome: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1995;9: 1140-1146
69. Spencer T, Biederman J, Steingard R, et al. Bupropion exacerbates tics in children with attention-deficit hyperactivity disorder and Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1993;32:211-214
70. Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 1993;50:286-288
71. McDougle CJ, Goodman WK, Leckman JF, et al. The efficacy of fluvoxamine in obsessive-compulsive disorder: effects of comorbid chronic tic disorder. J Clin Psychopharmacol 1993;13:354-358
72. McDougle CJ, Goodman WK, Price LH. Dopamine antagonists in tic-related and psychotic spectrum obsessive compulsive disorder. J Clin Psychiatry 1994;55(3, suppl):24-31
73. Riddle MA, Hardin MT, King RA, et al. Fluoxetine treatment of children and adolescents with Tourette's and obsessive compulsive disorders: preliminary clinical experience. J Am Acad Child Adolesc Psychiatry 1990; 29:45-48